With Two BCMA-Targeting Myeloma Treatments, Which Should Be First Choice?
Experts Weigh In On Positioning BMS/Bluebird’s Abecma And GSK’s Blenrep
Market Snapshot: GSK's Blenrep and BMS's Abecma are the first of many drugs for the late-line setting. In many cases, the CAR-T may be the first choice, but some patients are unable to handle it or risk progressing while awaiting treatment.
You may also be interested in...
Despite the net health benefits of Abecma, the price is too high, while Blenrep has low long-term value for the cost, according to ICER's benchmarks.
In this week's podcast version of Five Must-Know Things, hear about IP waivers for coronavirus vaccines; launch records for Pfizer’s COVID-19 vaccine; new potential delivery routes for booster vaccines; newcomers in the BCMA-targeting field; and a snapshot of the current state of play in global pharma R&D.
Idecabtagene vicleucel for fifth-line multiple myeloma lags GSK’s BCMA-targeting ADC Blenrep, but it is months ahead of J&J/Legend’s CAR-T. Abecma is BMS’s second CAR-T approval this year.